129 related articles for article (PubMed ID: 25964532)
1. Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy.
Klotz LV; Clevert DA; Scheckinger S; Strieth S; Eichhorn ME
Anticancer Res; 2015 May; 35(5):2571-6. PubMed ID: 25964532
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
[TBL] [Abstract][Full Text] [Related]
3. Correlation of contrast-enhanced ultrasound with two distinct types of blood vessels for the assessment of angiogenesis in lewis lung carcinoma.
Zhuo J; Fu W; Liu S
Ultraschall Med; 2014 Oct; 35(5):468-72. PubMed ID: 24327471
[TBL] [Abstract][Full Text] [Related]
4. Effects of low-frequency ultrasound and microbubbles on angiogenesis-associated proteins in subcutaneous tumors of nude mice.
Shen ZY; Shen E; Zhang JZ; Bai WK; Wang Y; Yang SL; Nan SL; Lin YD; Li Y; Hu B
Oncol Rep; 2013 Aug; 30(2):842-50. PubMed ID: 23707983
[TBL] [Abstract][Full Text] [Related]
5. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
6. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.
Lamuraglia M; Barrois G; Le Guillou-Buffello D; Santin M; Kerbol A; Comperat E; Coron A; Lucidarme O; Bridal SL
Technol Cancer Res Treat; 2020; 19():1533033819886896. PubMed ID: 32065066
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic Therapy Induces Hepatic Tumor Vascular Network Rearrangement to Receive Perfusion via the Portal Vein and Hepatic Artery.
Kang W; Lim JS; Park MS; Koh GY; Kim H
J Vasc Res; 2016; 53(1-2):72-82. PubMed ID: 27643516
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
[TBL] [Abstract][Full Text] [Related]
10. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
11. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M
Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
15. Vascular targeting tumor therapy: non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation.
Eichhorn ME; Klotz LV; Luedemann S; Strieth S; Kleespies A; Preissler G; Lindner M; Jauch KW; Reiser MF; Clevert DA
Cancer Biol Ther; 2010 May; 9(10):794-802. PubMed ID: 20234173
[TBL] [Abstract][Full Text] [Related]
16. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
17. Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US?
Forsberg F
Radiology; 2010 Feb; 254(2):317-8. PubMed ID: 20093504
[TBL] [Abstract][Full Text] [Related]
18. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
Osusky KL; Hallahan DE; Fu A; Ye F; Shyr Y; Geng L
Angiogenesis; 2004; 7(3):225-33. PubMed ID: 15609077
[TBL] [Abstract][Full Text] [Related]
19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
